Tecelra and MAGE-A4 TCR Therapy: Engineering Safer, High-Affinity Adoptive T-Cell Immunotherapy
Tecelra, an affinity-enhanced MAGE-A4–specific TCR approved for its efficacy against metastatic synovial sarcoma with minimal off-target risk. The gene therapy showed strong antigen-specific cytokine release, effective tumor cell killing in 2D and 3D models, and dose-dependent tumor regression with complete survival in vivo with manageable alloreactivity and limited cross-reactivity.